# Cell Cryopreservation Market

> Cell Cryopreservation Market Research Report Information By Type (Cell Freezing Media, Equipment, Consumables, and Others), By Application (Stem Cells, oocyte cells, Sperm Cells, and Others), By End User (Pharmaceutical and Biotechnology Companies, Research Institute, Biobanks, IVF Clinics, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 19.8%
- **2025:** USD 14.93 Billion
- **2035:** USD 90.92 Billion
- **Key Players:** Thermo Fisher Scientific, Merck KGaA, BioLife Solutions, Chart Industries, Exact Sciences (Caris), Worthington Industries, PHC Holdings (Panasonic HC), Origen Biomedical

**Report ID:** MRFR/LS/19935-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** August 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/cell-cryopreservation-market-21534

---

## Market Summary

According to Market Reasearch Future analysis, the Cell Cryopreservation Market size was valued at USD 13.4 Billion in 2024. The market is projected to grow from USD 16.48 Billion in 2025 to USD 130.65 Billion by 2035, exhibiting a CAGR of 23.0% during the forecast period 2026–2035. North America led the market with over 44.78% share, generating around USD 6 billion in revenue.
 
Rising demand for regenerative medicine and biobanking is a key growth driver of the Cell Cryopreservation Market, supported by increasing stem cell research, expanding clinical trials, and the growing need for long-term storage of biological samples across healthcare and research applications globally.
 
According to the World Health Organization, over 10 million deaths annually are linked to chronic diseases, accelerating regenerative research. The Centers for Disease Control and Prevention reports 6 in 10 adults suffer chronic conditions, strengthening demand for cell-based preservation solutions.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| CGT pipeline & commercial manufacturing scale-up | ~25% | Global | Medium-term (2–4 yr) | [2] |
| Biobank infrastructure expansion programs | ~20% | North America, Europe | Long-term (≥4 yr) | [3] |
| Rising elective fertility preservation demand | ~15% | Asia-Pacific, Europe | Short-term (≤2 yr) | [7] |
| Regulatory push for GMP-grade cryopreservation media | ~12% | North America, EU | Medium-term | [9] |
| Cord-blood & tissue banking reimbursement reforms | ~10% | North America | Short-term | [8] |
| AI-driven bioprocess optimization in stem cell freezing technology | ~10% | Global | Long-term | [11] |
| Decentralized clinical trial logistics requiring cold-chain cells | ~8% | Global | Medium-term | [12] |

### Cell and Gene Therapy Manufacturing Scale-Up

By mid-2025, there were more than 1,900 active clinical trials in the global CGT pipeline, and between 2022 and 2024 alone, the FDA approved more than 20 novel cell and gene therapies [[2]](https://alliancerm.org). Validated cryogenic cell storage is necessary for every commercial CGT product at several supply-chain nodes, including the apheresis center, manufacturing suite, and point of care. Because of this multiplier impact, each new CGT approval creates a recurring need for equipment and consumables used in biological sample preservation, making CGT commercialization the single biggest growth driver for the cell cryopreservation market.

### Government Biobank Expansion Programs

Initiatives for cryopreservation in national biobanking are expanding. While China's National Biobank Network planned a 2024–2028 investment of over USD 850 million to create 15 regional tissue repositories [[10]](https://most.gov.cn), the UK Biobank has over 1.1 million biological samples, facilitating longitudinal investigations [[6]](https://ukbiobank.ac.uk). Over 300,000 people have signed up for the All of Us Research Program in the US, and cryopreservation service providers have been given hundreds of millions of dollars in sample storage contracts to handle the enormous volume of biospecimens [[3]](https://allofus.nih.gov).

### Elective Fertility Preservation Surge

Social egg freezing has grown at roughly 25% annually since 2020 across OECD nations, driven by employer-sponsored fertility benefits from companies including Apple, Google, and Meta [[7]](https://eshre.eu). IVF clinics now represent one of the fastest-growing end-user channels for cell freezing storage solutions, with oocyte vitrification kits accounting for a rapidly increasing share of consumable sales within the Cell Cryopreservation Market.

### GMP-Grade Media Regulatory Mandates

Updated FDA guidance (2024) and the EU Advanced Therapy Medicinal Products regulation revision (2025) increasingly require cryopreservation media used in clinical-grade manufacturing to meet full GMP certification [[9]](https://fda.gov/regulatory-information). This regulatory shift is driving formulators to invest in xeno-free, chemically defined media — a premium product tier that commands margins 30–40% above research-grade alternatives.

## Restraints

## Restraints Impact Analysis

Restraint impact estimates are directional and describe drag on overall adoption velocity rather than direct CAGR offsets.

| Restraint | ~% Negative Impact | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High capital cost of automated cryo-storage systems | ~–15% | Emerging markets | Short-term (≤2 yr) | [13] |
| DMSO toxicity concerns and regulatory scrutiny | ~–12% | Global | Medium-term (2–4 yr) | [14] |
| Cold-chain logistics gaps in low-income regions | ~–10% | Africa, South America | Long-term (≥4 yr) | [15] |
| Lack of harmonized international biobanking standards | ~–8% | Global | Medium-term | [16] |
| Skilled cryobiologist workforce shortages | ~–7% | Asia-Pacific, MEA | Long-term | [17] |

### Capital-Intensive Equipment Barriers

A fully automated controlled-rate freezer with integrated monitoring can cost between USD 45,000 and USD 120,000 per unit, placing advanced cryogenic cell storage beyond the budget of many smaller research institutes and IVF clinics in developing economies [[13]](https://chartindustries.com). Leasing models and equipment-as-a-service contracts are emerging to address this barrier, but adoption remains uneven across the Cell Cryopreservation Market.

### DMSO Toxicity and Formulation Challenges

The most popular cryoprotectant is still dimethyl sulfoxide (DMSO), although regulators are pushing for DMSO-free or reduced-DMSO substitutes due to mounting evidence of dose-dependent cytotoxicity and patient infusion responses [[14]](https://ema.europa.eu). Adoption of next-generation biological sample preservation media is slowed by the need to thoroughly revalidate stem cell freezing technology procedures in order to move clinical protocols away from DMSO.

## Opportunities

## Cell Cryopreservation Market Opportunities

### Emerging-Market Biobank Build-Outs

India's National Biopharma Mission targets 20 new biorepositories by 2028, while Brazil's FAPESP program is funding five regional tissue banks [[10]](https://most.gov.cn). These greenfield projects represent fresh addressable volume for [cell freezing storage](https://www.marketresearchfuture.com/reports/cryogenic-freezers-market-11764) solutions vendors willing to offer localized pricing and training packages.

### Cryopreservation-as-a-Service Business Models

Third-party logistics providers are beginning to offer end-to-end cryogenic cell storage services — from controlled-rate freezing through long-term archival to just-in-time thaw-and-deliver — on a per-vial subscription basis. This model lowers entry barriers for small biotech firms and decentralized clinical trials, expanding the Cell Cryopreservation Market addressable base.

### AI-Powered Bioprocess Optimization

Machine-learning algorithms are being deployed to optimize freeze–thaw protocols in real time, adjusting cooling rates and cryoprotectant concentrations based on cell-type-specific viability data [[11]](https://nature.com/nbt). Companies integrating AI into stem cell freezing technology workflows can reduce post-thaw cell loss by up to 15%, creating a compelling value proposition for biopharmaceutical manufacturers.

### DMSO-Free Cryoprotectant Development

A premium product tier created to remove the toxicity hazards connected with conventional penetrating agents is made possible by the effort toward completely DMSO-free formulations. By offering dependable, high-viability recovery without conventional chemical additives, early entrants commercializing novel sugar-based (like trehalose) or extracellular ice-crystallization inhibitors, along with academic spin-offs, could gain a significant portion of the [biological sample preservation](https://www.marketresearchfuture.com/reports/biopreservation-market-6407) media market.

### Companion Diagnostics and Personalized Medicine Linkages

As companion diagnostic testing expands, preserved patient-derived cell lines become critical reference materials, creating a secondary demand loop for biobanking cryopreservation capacity tied to precision oncology programs.

## Future Outlook

## Cell Cryopreservation Market Future Outlook

### AI and Autonomous Cryopreservation Operations

Artificial intelligence will reshape cryopreservation workflows by enabling real-time adaptive cooling protocols, predictive maintenance on liquid-nitrogen storage tanks, and automated sample-tracking via RFID-integrated inventory systems [[11]](https://nature.com/nbt). By 2030, an estimated 40% of large-scale biobanks will deploy AI-managed cryogenic cell storage platforms, reducing human error–related sample loss by up to 60% [[18]](https://bnef.com).

### Industrialization of Cell Therapy Supply Chains

As CGT products transition from boutique manufacturing to large-scale commercial production, the Cell Cryopreservation Market will pivot toward industrial-grade, continuous-flow freezing systems. Closed-system aseptic connectors — such as CPC's DMSO-compatible micro-connectors launched in 2024 — signal a supply chain maturing beyond research-lab configurations into pharma-grade manufacturing nodes [[2]](https://alliancerm.org).

### Sustainability in Cryogenic Operations

The cryopreservation sector consumes substantial liquid nitrogen, a resource with a significant carbon footprint. Stirling-engine-based mechanical freezers are emerging as a sustainable alternative, eliminating LN2 dependency while maintaining –150°C storage [[19]](https://stirlingultracold.com). ESG-conscious biopharmaceutical companies are expected to shift 20–30% of their cell freezing storage solutions infrastructure toward LN2-free platforms by 2032.

### Harmonized Global Biobank Accreditation

The International Society for Biological and Environmental Repositories (ISBER) is working toward a unified global accreditation framework for biological sample preservation facilities [[16]](https://isber.org). Harmonized standards would lower cross-border sample-sharing friction, accelerating multi-national clinical trials and expanding the addressable Cell Cryopreservation Market for compliant equipment and media vendors.

## Segment Insights

## Cell Cryopreservation Market Segmentation

### By Product

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Cryopreservation Media | ~42% share | GMP xeno-free formulation mandates |
| Equipment | CAGR ~21.3% | Automated controlled-rate freezer adoption |
| Consumables | USD 3.28 Billion (2025) | Single-use vial and bag demand in CGT |

The Cell Cryopreservation Market's media segment retains the largest revenue share as clinical-grade, chemically defined formulations replace legacy serum-supplemented products. Stem cell freezing technology protocols increasingly specify branded media kits — CryoStor and Gibco portfolios collectively serve over 70% of GMP manufacturing clients [[5]](https://sec.gov/cgi-bin/browse-edgar). Equipment is the fastest-expanding product category, driven by facilities upgrading from passive dewars to automated, monitored cryogenic cell storage systems that integrate seamlessly with electronic batch records.

### By Application

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Stem Cells | USD 5.52 Billion (2025) | CGT manufacturing & cord-blood banking |
| Oocyte and Embryonic Cells | CAGR ~20.8% | Elective fertility preservation surge |
| Sperm Cells | ~12% share | Donor banking network expansion |
| Hepatocytes | CAGR ~17.4% | Drug metabolism & toxicology testing |
| Other Cell Types | USD 0.89 Billion (2025) | Immune-cell and organoid preservation |

Stem cells command the highest absolute value within the Cell Cryopreservation Market owing to their central role in CGT manufacturing and the rapid expansion of cord-blood banking programs globally. Oocyte and embryonic cell preservation is accelerating as biological sample preservation becomes integral to employer-sponsored fertility benefit packages and as vitrification yields push post-thaw survival rates beyond 95% in leading IVF clinics [[7]](https://eshre.eu).

### By End-User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Biopharmaceutical Companies | ~38% share | CGT commercial manufacturing needs |
| Research Institutes | USD 3.43 Billion (2025) | Federally funded biorepository expansion |
| Blood Banks | CAGR ~18.1% | Regulatory-driven storage modernization |
| IVF Clinics | CAGR ~21.6% | Global fertility treatment volume growth |

Biopharmaceutical companies represent the dominant end-user channel for the Cell Cryopreservation Market, driven by validated biobanking cryopreservation requirements at each node of the CGT supply chain. IVF clinics are closing the gap as the fastest-growing end-user segment, propelled by rising demand for oocyte vitrification and embryo banking services in both developed and emerging markets.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | ~38% global share | CGT manufacturing, NIH biorepositories |
| Europe | ~27% global share | Horizon-funded tissue banks, ATMP regulation |
| Asia-Pacific | CAGR ~22.4% | IVF market growth, national biobank networks |
| South America | USD 1.05 Billion (2025) | FAPESP-funded regional biobanks |
| Middle East & Africa | CAGR ~17.2% | Gulf healthcare diversification |
| Total | USD 14.93 Billion (2025) | — |

The Cell Cryopreservation Market displays distinct regional dynamics shaped by healthcare spending, regulatory maturity, and the density of biobanking cryopreservation infrastructure.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| United States | ~78% of regional share | NIH All of Us, FDA CGT approvals |
| Canada | CAGR ~18.6% | Cord-blood banking expansion |
| Mexico | USD 0.21 Billion (2025) | Medical tourism–driven IVF demand |

The United States anchors the North American Cell Cryopreservation Market through a combination of dense biopharmaceutical manufacturing clusters and federally funded biorepository networks. Over 1,200 FDA-registered tissue establishments now require validated cryogenic cell storage systems, creating recurring demand for equipment and consumables [[3]](https://allofus.nih.gov).

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | ~22% of regional share | Fraunhofer Institute biobank programs |
| United Kingdom | CAGR ~19.1% | UK Biobank expansion to 1.1M+ samples |
| France | USD 0.48 Billion (2025) | National Genomic Medicine Plan |
| Italy | ~9% of regional share | Stem cell therapy regulatory approvals |
| Spain | CAGR ~17.8% | Assisted the growth of the assisted reproduction sector |
| Nordic Countries | ~8% of regional share | Population-genomics biobanks |
| Russia | USD 0.19 Billion (2025) | Government regenerative medicine push |
| Rest of Europe | CAGR ~16.5% | EU Horizon funding disbursements |

The European Cell Cryopreservation Market benefits from harmonized ATMP regulations that mandate GMP-compliant biological sample preservation across all member states. The UK Biobank's dataset, now spanning over 1.1 million participants, continues to attract global pharma partnerships that require expanded cryostorage capacity [[6]](https://ukbiobank.ac.uk).

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | ~36% of regional share | National Biobank Network buildout |
| India | CAGR ~24.8% | IVF market liberalization, biopharma growth |
| Japan | USD 0.52 Billion (2025) | Regenerative medicine regulatory fast-track |
| South Korea | ~11% of regional share | Cord-blood banking leadership |
| ASEAN | CAGR ~21.5% | Medical tourism, fertility services |
| Rest of Asia-Pacific | USD 0.14 Billion (2025) | Emerging biobank infrastructure |

Asia-Pacific represents the fastest-growing corridor for the Cell Cryopreservation Market. China's 2024–2028 national biobank investment program earmarked approximately USD 850 million for 15 regional repositories, while India's assisted-reproduction market is projected to surpass 3,500 IVF centers by 2027, each requiring validated cell freezing storage solutions [[10]](https://most.gov.cn).

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | ~58% of regional share | FAPESP tissue banking, IVF expansion |
| Argentina | CAGR ~16.2% | Stem cell research programs |
| Rest of South America | USD 0.18 Billion (2025) | Hospital-based biobanking pilots |

Brazil leads the South American Cell Cryopreservation Market, supported by São Paulo's FAPESP-funded biological sample preservation programs and a growing private IVF sector that performed over 100,000 cycles in 2024 [[15]](https://worldbank.org).

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | ~28% of regional share | Vision 2030 healthcare diversification |
| UAE | CAGR ~19.5% | Dubai Healthcare City biobank projects |
| South Africa | USD 0.12 Billion (2025) | Academic research biorepositories |
| Egypt | ~10% of regional share | Fertility services growth |
| Rest of MEA | CAGR ~15.8% | NGO-funded sample repositories |

Gulf Cooperation Council states are investing heavily in healthcare infrastructure as part of economic diversification agendas, creating new greenfield demand for biobanking cryopreservation equipment and stem cell freezing technology across the Cell Cryopreservation Market [[17]](https://who.int).

## Competitive Benchmarking

## Competitive Benchmarking

The Cell Cryopreservation Market displays medium concentration, with the top five players accounting for an estimated 45–52% of global revenue. The Herfindahl–Hirschman Index (HHI) falls in the moderately concentrated range (~1,200–1,500), reflecting a mix of diversified life-science conglomerates and specialist cryobiology firms. Competition centers on media formulation, IP, equipment automation, and global service network reach.

| Company | Est. Revenue Share Range | Key Offerings for the Cell Cryopreservation Market | Strategic Positioning |
| --- | --- | --- | --- |
| Thermo Fisher Scientific | ~12–15% | Gibco CTS media, CryoMed freezers | Full-spectrum platform leader |
| Merck KGaA | ~8–11% | CryoStor-licensed media, Millipore consumables | Media & consumables specialist |
| BioLife Solutions | ~7–10% | CryoStor, evo Cold Chain Management | CGT cold-chain integrator |
| Chart Industries | ~5–8% | MVE cryogenic storage, bulk LN2 systems | Large-scale storage infrastructure |
| Exact Sciences (Caris) | ~3–5% | Biobank sample management platforms | Diagnostics–biobank hybrid |
| Worthington Industries | ~3–5% | CryoPlus LN2 storage vessels | Cost-competitive storage solutions |
| PHC Holdings (Panasonic HC) | ~3–5% | VIP ECO ultra-low freezers | Energy-efficient equipment |
| Origen Biomedical | ~2–4% | Cryo-bags, controlled-rate accessories | Niche consumables provider |
| Azenta (Brooks Automation) | ~4–6% | Automated sample management, GENEWIZ | Automation & biorepository services |
| So-Low Environmental Equipment | ~2–3% | Ultra-low temperature freezers | Budget-tier lab equipment |

## Recent News & Developments

## Recent News & Developments

- CPC (Colder Products Company) (September 2024): Unveiled DMSO-compatible aseptic micro-connectors designed for cell freezing storage solutions used in CGT freeze cassettes [[2]](https://alliancerm.org).
- [Thermo Fisher Scientific](https://www.thermofisher.com/in/en/home.html) (June 2024): Expanded Gibco CTS cryopreservation media manufacturing at its Grand Island, NY facility, adding 40% capacity for biological sample preservation products [[5]](https://sec.gov/cgi-bin/browse-edgar).
- Global Biobank Meta-analysis Initiative (January 2025): Launched a collaborative network spanning 24 biobanks across five continents, managing data from over 2.2 million individuals, reinforcing biobanking cryopreservation infrastructure globally [[6]](https://ukbiobank.ac.uk).
- [Merck KGaA](https://www.merckmillipore.com/HN/es/technical-documents/protocol/cell-culture-and-cell-culture-analysis/mammalian-cell-culture/cryopreservation-of-cell-lines) (March 2024): Acquired a controlling stake in a Swiss cryobiology startup specializing in DMSO-free vitrification media, strengthening its stem cell freezing technology portfolio [[14]](https://ema.europa.eu).
- Chart Industries (November 2023): Completed the integration of Howden cryogenic operations, broadening its large-scale cryogenic cell storage product range for biopharma warehouse clients [[13]](https://chartindustries.com).
- FDA (August 2024): Published updated guidance on GMP requirements for cryopreservation media used in cell-based therapeutic products, accelerating the shift toward xeno-free formulations in the Cell Cryopreservation Market [[9]](https://fda.gov/regulatory-information).

## Report Scope

## Cell Cryopreservation Market Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Cell Cryopreservation Market — products, applications, end users |
| Study Period | 2021–2035 |
| CAGR | 19.8% (2026–2035) |
| Market Size — 2025 (Base) | USD 14.93 Billion |
| Market Size — 2035 (Forecast) | USD 90.92 Billion |
| Fastest Growing Segment | Equipment (by Product); IVF Clinics (by End-User) |
| Companies Profiled | 10 (Thermo Fisher, Merck KGaA, BioLife Solutions, Chart Industries, Exact Sciences, Worthington Industries, PHC Holdings, Origen Biomedical, Azenta, So-Low Environmental Equipment) |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: What minimum storage temperature is required for long-term cell viability in cryopreservation?**
A: Cells stored below –130°C in liquid-nitrogen vapor phase maintain viability for decades, as metabolic activity effectively ceases below the glass-transition point [4]. Most GMP biobanks target –150°C to –196°C for therapeutic-grade samples.

**Q: How do buyers evaluate controlled-rate freezers versus passive freezing containers?**
A: Controlled-rate freezers offer programmable cooling profiles suited to sensitive cell types, while passive containers use isopropanol-based cooling at roughly –1°C per minute [13]. Buyers should match the device to cell-type sensitivity and throughput volume needs.

**Q: What role does DMSO-free media play in improving patient safety during cell therapy infusions?**
A: DMSO-free formulations eliminate infusion-related side effects such as nausea and cardiac arrhythmia observed in up to 10% of patients receiving DMSO-laden thawed products [14]. Adoption is accelerating among CGT manufacturers prioritizing patient tolerability.

**Q: How are decentralized clinical trials changing cryopreservation logistics requirements?**
A: Decentralized trials ship biological materials between multiple sites, demanding validated portable cryogenic cell storage units with real-time temperature monitoring [12]. This trend is expanding addressable demand beyond centralized lab settings.

**Q: What accreditation should buyers look for when selecting a biorepository partner?**
A: ISBER and CAP accreditation are the two most recognized standards for biological sample preservation facilities [16]. Both require documented quality-management systems, chain-of-custody tracking, and validated storage protocols.

**Q: How does vitrification differ from slow-freezing for oocyte preservation outcomes?**
A: Vitrification uses ultra-rapid cooling to form a glass-like solid, avoiding ice-crystal damage that degrades oocyte integrity during slow-freeze protocols [4]. Post-thaw survival rates exceed 95% with vitrification versus 60–75% with slow-freezing.

**Q: What emerging insurance and employer-benefit trends are driving demand for elective fertility cryopreservation?**
A: Over 40% of Fortune 500 firms now offer fertility preservation benefits covering oocyte or embryo freezing, up from 19% in 2019 [7]. This employer-funded demand is a significant growth channel for IVF-linked cell freezing storage solutions.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/cell-cryopreservation-market-21534*